ERBB2 and breast cancer: To explore the utility of these new therapies as neoadjuvant treatments, it may be required to identify significant prognostic indicators for predicting overall survival or CSS for NAE-treated patients with ER-positive and HER2-negative breast cancer before conducting prospective clinical trials of new drugs in the neoadjuvant setting.